Quantcast
Last updated on April 16, 2014 at 13:58 EDT

Latest Ribonucleases Stories

2014-03-17 12:27:32

--Novel Biologic Targets Innovative New Mechanism in Lupus-- SEATTLE, March 17, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of clinical studies with its lead compound RSLV-132. Resolve administered the first doses to humans of RSLV-132 its first-in-class targeted nuclease therapy designed to decrease the burden of circulating RNA-containing immune complexes in SLE patients. Ongoing studies are designed to evaluate the safety, tolerability,...

2013-06-06 20:02:51

Structural and molecular differences between human Argonaute proteins reveal essential elements for RNA-slicing Human Argonautes (hAgo), are key proteins involved in a process known as RNA interference. RNAi, as it is often called, is a mechanism that cells use to regulate gene expression. Human Argonaute-2 (hAgo2) is known as "slicer" for its unique ability among the 4 human Argonaute proteins to directly cut messenger RNA -- which carries the information coded in genomic DNA to make a...

2012-07-27 02:24:04

PETALUMA, Calif., July 27, 2012 /PRNewswire/ -- Labcon North America (www.labcon.com), the world's leading manufacturer of Earth Friendly laboratory disposables, announced today that it has added certification testing for Adenosine Triphosphate (ATP) to its portfolio of standard Lot by Lot testing. ATP testing joins an unrivaled list of standard certifications including Dnase, Rnase, DNA, Endotoxin, Pyrogen, Heavy Metals, Sterility, Protease, Oleamide, DiHemda, and BPA that are now...

2012-06-21 23:41:05

Researchers at the Whitehead Institute and Memorial Sloan-Kettering Cancer Center have defined and analyzed the crystal structure of a yeast Argonaute protein bound to RNA. This complex plays a key role in the RNA interference (RNAi) pathway that silences gene expression. Describing the molecular structure of a eukaryotic Argonaute protein has been a goal of the RNAi field for close to a decade. "You can learn a lot from biochemical experiments, but to more fully understand a protein like...

2012-06-04 02:26:09

NEW YORK, June 4, 2012 /PRNewswire/ -- Exosome Diagnostics today announced it has reached agreement with Life Technologies to use the Applied Biosystems® (ABI) 7500 Fast Dx Real-Time PCR Instrument for the Company's exosome biofluid in-vitro diagnostics oncology program. Exosome Diagnostics plans to validate the ABI instrument platform with exosome biofluid RNA isolation technology kits in upcoming multi-center clinical trials in brain cancer and prostate cancer beginning in...

2012-03-28 02:24:16

NEW YORK, March 28, 2011 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized and non-invasive cancer diagnostics, today announced that Kapil Dhingra, M.B, B.S., has joined the Exosome Diagnostics Board of Directors. "I am delighted to join the Board of Exosome Diagnostics at this critical stage in the evolution of the company. Cancer treatment is becoming increasingly personalized. The ability to perform repeated,...

2012-02-06 07:00:00

WASHINGTON and NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Accelerate Brain Cancer Cure (ABC2) and Exosome Diagnostics are collaborating with leading academic medical centers to accelerate clinical validation of Exosome's blood and cerebrospinal fluid-based molecular diagnostics technology in brain cancer. The collaboration will explore the capabilities of Exosome RNA biofluid-based diagnostic technology for early identification, progression monitoring and disease risk stratification...

2012-02-01 07:00:00

MUNICH, Feb. 1, 2012 /PRNewswire/ -- Exosome Diagnostics GmbH, a subsidiary of Exosome Diagnostics, Inc., and the Department of Dermatology at the Ludwig Maximilian University (LMU) announces the awarding of a EUR one million grant from the German Federal Ministry for Education and Research (BMBF) to develop blood-based diagnostic tests from the stable RNA content accessible in plasma-derived exosomes. The grant will help fund development of exosome-based diagnostics technology to...

2011-10-04 06:00:00

NEW YORK, Oct. 4, 2011 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine, today announced the appointment of David Okrongly, Ph.D., as chief operating officer, Michael Donovan, M.D., Ph.D., as chief medical officer, and Sally Bowden, Ph.D., as director of regulatory affairs. Raphael Bueno, M.D., associate chief of cardiothoracic surgery Harvard University and Michael Manyak, M.D., FACS, executive director...

2011-01-20 16:47:53

For years, RNA has seemed an elusive tool in nanotechnology research"”easily manipulated into a variety of structures, yet susceptible to quick destruction when confronted with a commonly found enzyme. "The enzyme RNase cuts RNA randomly into small pieces, very efficiently and within minutes," explains Peixuan Guo, PhD, Dane and Mary Louise Miller Endowed Chair and professor of biomedical engineering at the University of Cincinnati (UC). "Moreover, RNase is present everywhere, making...